STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Camp4 Therapeutics Corp SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Camp4 Therapeutics Schedule 13G/A: HarbourVest-affiliated entities report beneficial ownership of 1,271,948 shares of Camp4 common stock, representing 2.7% of the class. The shares are owned directly by SMRS-TOPE LLC, which holds sole voting and dispositive power over all 1,271,948 shares. HarbourVest Partners, LLC, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared voting and dispositive power but disclaim beneficial ownership. The filing includes a joint filing agreement among the reporting persons and is based on 46,842,126 shares outstanding used to calculate the 2.7% stake.

Positive
  • Transparency provided by timely Schedule 13G/A filing clarifies ownership structure and voting/dispositive powers
  • Non-controlling stake (2.7%) reduces near-term takeover or control concerns
Negative
  • None.

Insights

TL;DR: HarbourVest-linked entities disclosed a passive 2.7% stake, below the 5% threshold that typically triggers activist signaling.

The 2.7% position indicates a meaningful but non-controlling interest. Ownership is held directly by SMRS-TOPE LLC with sole voting and dispositive power, while parent entities disclaim direct beneficial ownership. For investors, this is a transparency filing rather than a change in control signal; no additional economic or strategic terms are reported.

TL;DR: This amendment clarifies ownership and control paths but shows no group intent to assert control or exercise activism.

The filing clarifies the ownership chain: HarbourVest entities are connected through manager/general partner relationships, but SMRS-TOPE LLC holds the actual shares and sole voting power. The disclaimers by HarbourVest entities are standard. There is no indication of coordinated group action, and the position size remains below thresholds that typically prompt governance changes.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



HarbourVest Partners L.P.
Signature:By: HarbourVest Partners, LLC, its General Partner; /s/ Adam Freedman
Name/Title:Adam Freedman; Chief Compliance Officer
Date:10/01/2025
HarbourVest Partners, LLC
Signature:/s/ Adam Freedman
Name/Title:Adam Freedman; Chief Compliance Officer
Date:10/01/2025
SMRS-TOPE LLC
Signature:By: HVST-TOPE LLC, its Managing Member; HarbourVest Partners L.P., its Manager; HarbourVest Partners, LLC, its General Partner; /s/ Adam Freedman
Name/Title:Adam Freedman; Chief Compliance Officer
Date:10/01/2025
HVST-TOPE LLC
Signature:By: HarbourVest Partners L.P., its Manager; HarbourVest Partners, LLC, its General Partner; /s/ Adam Freedman
Name/Title:Adam Freedman; Chief Compliance Officer
Date:10/01/2025

FAQ

How many Camp4 (CAMP) shares do HarbourVest entities report owning?

They report beneficial ownership of 1,271,948 shares of Camp4 common stock.

What percent of CAMP does the reported stake represent?

The filing states the stake represents 2.7% of the outstanding common stock based on 46,842,126 shares.

Which entity holds the shares and who has voting power?

SMRS-TOPE LLC owns the shares directly and has sole voting and dispositive power over all 1,271,948 shares.

Do HarbourVest entities claim beneficial ownership of the shares?

HarbourVest Partners, LLC, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared power but they disclaim beneficial ownership in the filing.

Does this filing indicate an intent to acquire control of CAMP?

No. The disclosed 2.7% stake is below 5% and the filing contains no statements indicating a control intent.
Camp4 Therapeutics Corp.

NASDAQ:CAMP

CAMP Rankings

CAMP Latest News

CAMP Latest SEC Filings

CAMP Stock Data

164.55M
10.47M
35.19%
51.76%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE